Hanseatic Management Services Inc. Makes New $781,000 Investment in CareDx, Inc (NASDAQ:CDNA)

Hanseatic Management Services Inc. acquired a new position in shares of CareDx, Inc (NASDAQ:CDNA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 24,998 shares of the company’s stock, valued at approximately $781,000.

Other large investors also recently added to or reduced their stakes in the company. ClariVest Asset Management LLC increased its holdings in CareDx by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 64,027 shares of the company’s stock worth $994,000 after purchasing an additional 1,810 shares during the period. GAMMA Investing LLC increased its holdings in CareDx by 1,021.8% during the 2nd quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock worth $34,000 after purchasing an additional 2,013 shares during the period. nVerses Capital LLC increased its holdings in CareDx by 175.0% during the 3rd quarter. nVerses Capital LLC now owns 3,300 shares of the company’s stock worth $103,000 after purchasing an additional 2,100 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in CareDx by 8.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,396 shares of the company’s stock worth $312,000 after purchasing an additional 2,344 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in CareDx by 13.4% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 21,164 shares of the company’s stock worth $329,000 after purchasing an additional 2,503 shares during the period.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. BTIG Research reduced their price objective on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday. Craig Hallum lifted their price target on CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Wells Fargo & Company began coverage on CareDx in a report on Tuesday, August 27th. They issued an “underweight” rating and a $28.00 price target on the stock. The Goldman Sachs Group lifted their price target on CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Finally, StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.60.

Insider Transactions at CareDx

In other news, Director Peter Maag sold 35,552 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $33.04, for a total value of $1,174,638.08. Following the completion of the sale, the director now owns 330,024 shares of the company’s stock, valued at $10,903,992.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other CareDx news, insider Alexander L. Johnson sold 34,231 shares of CareDx stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $33.55, for a total transaction of $1,148,450.05. Following the completion of the sale, the insider now owns 284,983 shares of the company’s stock, valued at approximately $9,561,179.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Peter Maag sold 35,552 shares of CareDx stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $33.04, for a total value of $1,174,638.08. Following the sale, the director now directly owns 330,024 shares of the company’s stock, valued at approximately $10,903,992.96. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,340 shares of company stock valued at $3,025,415 in the last quarter. 4.90% of the stock is currently owned by corporate insiders.

CareDx Price Performance

CareDx stock opened at $23.21 on Thursday. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -8.60 and a beta of 1.80. CareDx, Inc has a 1-year low of $6.11 and a 1-year high of $34.84. The business has a fifty day moving average price of $27.56 and a 200-day moving average price of $20.97.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. The firm had revenue of $82.88 million during the quarter, compared to analysts’ expectations of $80.04 million. CareDx had a negative return on equity of 53.65% and a negative net margin of 53.73%. The business’s quarterly revenue was up 23.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.43) EPS. On average, equities research analysts anticipate that CareDx, Inc will post -0.83 earnings per share for the current fiscal year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.